Vitiligo
☆ Dina hasil Stiftung Warentest 2022 ti Jerman, kapuasan konsumen sareng ModelDerm ngan ukur langkung handap tibatan konsultasi telemedicine anu mayar.
Vitiligo tina ramo leuwih hese pikeun ngubaran ti wewengkon séjén. Kumisan ti keur cosmetically unsightly, vitiligo téh normal tur teu tepa. Dina dermatology, perlakuan paling mujarab nyaéta phototherapy atawa perlakuan laser (excimer) 2-3 kali saminggu salila sahenteuna 1 taun. Upami anjeun teu tiasa sering ka rumah sakit kusabab alesan kauangan atanapi kusabab sibuk, anjeun tiasa nyobian mesin fototerapi anu disatujuan pikeun dianggo di bumi.
Vitiligo kongkolak panon
Vitiligo dina leungeun
References
Vitiligo mangrupikeun gangguan kulit umum anu nyababkeun bintik-bintik kulit bodas kusabab leungitna melanosit. Panaliti anyar nunjukkeun yén éta mangrupikeun panyakit otoimun. Sanaos sering ditingali salaku masalah kosmetik, éta tiasa mangaruhan pisan kana karaharjaan méntal sareng kahirupan sapopoé. Dina 2011, para ahli ngagolongkeun hiji tipe disebut segmental vitiligo misah ti batur.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Pasién vitiligo aktif gaduh sababaraha pilihan terapi, sapertos glukokortikoid sistemik, fototerapi, sareng imunosupresan sistemik. Pasén vitiligo stabil bisa manggihan relief tina kortikosteroid topikal, inhibitor calcineurin topical, phototherapy, sarta prosedur cangkok. Kamajuan panganyarna dina pamahaman prosés dasar vitiligo parantos nyababkeun pangembangan terapi anu dituju. Ayeuna, sambetan JAK mangrupikeun anu paling ngajangjikeun, nawiskeun kasabaran anu saé sareng hasil fungsional, sanaos résiko ngaktifkeun inféksi laten sareng efek samping sistemik anu umum sareng agén imunosupresif sanés. Panalungtikan lumangsung boga tujuan pikeun ngaidentipikasi cytokines konci aub dina ngembangkeun vitiligo urang (IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, TNF) . Blocking cytokines ieu geus ditémbongkeun jangji dina model sato jeung sababaraha pasien. Salaku tambahan, panyilidikan kana miRNA-based therapeutics sareng adoptive Treg cell therapy nuju dijalankeun.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Teu aya ubar anu dipikanyaho pikeun vitiligo. Pikeun anu kulitna hampang, tabir surya sareng makeup mangrupikeun hal anu biasana disarankeun. pilihan perlakuan séjén bisa ngawengku creams stéroid atawa phototherapy.
○ Perlakuan
#Phototherapy
#Excimer laser
#Tacrolimus ointment